Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 44.3% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 32,918 shares of the pharmaceutical company’s stock after purchasing an additional 10,108 shares during the period. Citizens Financial Group Inc. RI’s holdings in Vertex Pharmaceuticals were worth $14,655,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Activest Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals in the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 45 shares during the period. Access Investment Management LLC purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $27,000. Flaharty Asset Management LLC purchased a new stake in Vertex Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.6%

Shares of Vertex Pharmaceuticals stock opened at $437.15 on Friday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The firm has a market capitalization of $110.91 billion, a PE ratio of 31.25 and a beta of 0.36. The firm’s 50-day moving average price is $408.04 and its 200 day moving average price is $427.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business earned $4.38 EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VRTX. Royal Bank Of Canada lowered their price target on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 4th. Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their target price for the stock from $458.00 to $456.00 in a research note on Thursday, September 25th. Wall Street Zen cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Stifel Nicolaus reduced their price target on Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Finally, Leerink Partnrs upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $491.95.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.